

SAFETY DATA SHEET



Betamethasone / Salicylic Acid Ointment Formulation



Version 3.7 Revision Date: 04/09/2021 SDS Number: 1841153-00012 Date of last issue: 10/10/2020
Date of first issue: 08/21/2017

SECTION 1. IDENTIFICATION

Product name : Betamethasone / Salicylic Acid Ointment Formulation

Manufacturer or supplier's details

Company name of supplier : Organon & Co.
Address : 30 Hudson Street, 33rd floor
Jersey City, New Jersey, U.S.A 07302
Telephone : 551-430-6000
Emergency telephone : 215-631-6999
E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Serious eye damage : Category 1
Reproductive toxicity : Category 1B
Specific target organ toxicity - repeated exposure : Category 1 (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland)

GHS label elements

Hazard pictograms :

Signal Word : Danger

Hazard Statements : H318 Causes serious eye damage.
H360D May damage the unborn child.
H372 Causes damage to organs (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) through prolonged or repeated exposure.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust, fume, gas, mist, vapors or spray.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:

SAFETY DATA SHEET



Betamethasone / Salicylic Acid Ointment Formulation



Version 3.7 Revision Date: 04/09/2021 SDS Number: 1841153-00012 Date of last issue: 10/10/2020
Date of first issue: 08/21/2017

P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER.

P308 + P313 IF exposed or concerned: Get medical attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Petrolatum	8009-03-8	86.93
Paraffin oil	8012-95-1	10
Salicylic acid	69-72-7	3
Betamethasone	378-44-9	0.064

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention immediately.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Causes serious eye damage.
May damage the unborn child.
Causes damage to organs through prolonged or repeated exposure.
- Protection of first-aiders : First Aid responders should pay attention to self-protection,

SAFETY DATA SHEET



Betamethasone / Salicylic Acid Ointment For- mulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
3.7	04/09/2021	1841153-00012	Date of first issue: 08/21/2017

Notes to physician : and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

SAFETY DATA SHEET



Betamethasone / Salicylic Acid Ointment For- mulation

Version 3.7 Revision Date: 04/09/2021 SDS Number: 1841153-00012 Date of last issue: 10/10/2020
Date of first issue: 08/21/2017

- Advice on safe handling : Do not get on skin or clothing.
Do not breathe dust, fume, gas, mist, vapors or spray.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Organic peroxides
Explosives
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis	
Petrolatum	8009-03-8	TWA (Mist)	5 mg/m ³	OSHA Z-1	
		TWA (Inhalable particulate matter)	5 mg/m ³	ACGIH	
		TWA (Mist)	5 mg/m ³	NIOSH REL	
		ST (Mist)	10 mg/m ³	NIOSH REL	
Paraffin oil	8012-95-1	TWA (Mist)	5 mg/m ³	OSHA Z-1	
		TWA (Inhalable particulate matter)	5 mg/m ³	ACGIH	
		TWA (Mist)	5 mg/m ³	NIOSH REL	
		ST (Mist)	10 mg/m ³	NIOSH REL	
Salicylic acid	69-72-7	TWA	100 µg/m ³ (OEB 2)	Internal	
		Further information: DSEN			
		Wipe limit	100 µg/100 cm ²	Internal	
Betamethasone	378-44-9	TWA	1 µg/m ³ (OEB 4)	Internal	
		Further information: Skin			
		Wipe limit	10 µg/100 cm ²	Internal	

- Engineering measures : Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying

SAFETY DATA SHEET



Betamethasone / Salicylic Acid Ointment Formulation



Version 3.7 Revision Date: 04/09/2021 SDS Number: 1841153-00012 Date of last issue: 10/10/2020
Date of first issue: 08/21/2017

from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies.

Personal protective equipment

- Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
-

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

- Appearance : ointment
- Color : white, translucent
-

SAFETY DATA SHEET



Betamethasone / Salicylic Acid Ointment Formulation



Version 3.7 Revision Date: 04/09/2021 SDS Number: 1841153-00012 Date of last issue: 10/10/2020
Date of first issue: 08/21/2017

Odor : No data available

Odor Threshold : No data available

pH : 4.6 - 5.3

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not classified as a flammability hazard

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

Betamethasone / Salicylic Acid Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
3.7	04/09/2021	1841153-00012	Date of first issue: 08/21/2017

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity	:	Acute toxicity estimate: > 5,000 mg/kg Method: Calculation method
Acute inhalation toxicity	:	Acute toxicity estimate: 7.5 mg/l Exposure time: 4 h Test atmosphere: dust/mist Method: Calculation method
Acute dermal toxicity	:	Acute toxicity estimate: > 5,000 mg/kg Method: Calculation method

Components:**Petrolatum:**

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg Method: OECD Test Guideline 401 Remarks: Based on data from similar materials
Acute dermal toxicity	:	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 402 Assessment: The substance or mixture has no acute dermal toxicity Remarks: Based on data from similar materials

Paraffin oil:

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg

Betamethasone / Salicylic Acid Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
3.7	04/09/2021	1841153-00012	Date of first issue: 08/21/2017

Assessment: The substance or mixture has no acute dermal toxicity

Salicylic acid:

Acute oral toxicity : LD50 (Mouse): 480 mg/kg
LD50 (Rat): 891 mg/kg
LD50 (Rabbit): 1,300 mg/kg

Acute inhalation toxicity : LC50 (Rat): 0.9 mg/l
Exposure time: 1 h

Acute dermal toxicity : LD50 (Rat): 2,000 mg/kg
LD50 (Rabbit): 10,000 mg/kg

Betamethasone:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
LD50 (Mouse): > 4,500 mg/kg

Acute inhalation toxicity : LC50 (Rat): 0.4 mg/l
Exposure time: 4 h

Skin corrosion/irritation

Not classified based on available information.

Components:**Petrolatum:**

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation
Remarks : Based on data from similar materials

Paraffin oil:

Species : Rabbit
Result : No skin irritation

Salicylic acid:

Result : Skin irritation

Betamethasone:

Species : Rabbit
Result : Mild skin irritation

Serious eye damage/eye irritation

Causes serious eye damage.

Betamethasone / Salicylic Acid Ointment Formulation

Version 3.7 Revision Date: 04/09/2021 SDS Number: 1841153-00012 Date of last issue: 10/10/2020
Date of first issue: 08/21/2017

Components:**Petrolatum:**

Species : Rabbit
Result : No eye irritation
Method : OECD Test Guideline 405
Remarks : Based on data from similar materials

Paraffin oil:

Species : Rabbit
Result : No eye irritation

Salicylic acid:

Species : Rabbit
Remarks : Severe eye irritation

Betamethasone:

Species : Rabbit
Result : No eye irritation

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**Petrolatum:**

Test Type : Buehler Test
Routes of exposure : Skin contact
Species : Guinea pig
Result : negative
Remarks : Based on data from similar materials

Salicylic acid:

Test Type : Local lymph node assay (LLNA)
Species : Mouse
Result : negative

Betamethasone:

Routes of exposure : Dermal
Species : Guinea pig
Result : Weak sensitizer

Germ cell mutagenicity

Not classified based on available information.

Betamethasone / Salicylic Acid Ointment For- mulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
3.7	04/09/2021	1841153-00012	Date of first issue: 08/21/2017

Components:**Petrolatum:**

- Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro
Result: negative
Remarks: Based on data from similar materials
- Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Method: OECD Test Guideline 474
Result: negative
Remarks: Based on data from similar materials

Salicylic acid:

- Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
- Genotoxicity in vivo : Test Type: Mammalian bone marrow sister chromatid exchange
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative
- Test Type: Sister chromatid exchange analysis in spermatogonia
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Betamethasone:

- Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
- Test Type: In vitro mammalian cell gene mutation test
Result: negative
- Test Type: Chromosome aberration test in vitro
Result: positive
- Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Oral
Result: equivocal
- Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Betamethasone / Salicylic Acid Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
3.7	04/09/2021	1841153-00012	Date of first issue: 08/21/2017

Carcinogenicity

Not classified based on available information.

Components:**Petrolatum:**

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	2 Years
Result	:	negative

Salicylic acid:

Species	:	Mouse
Application Route	:	Skin contact
Exposure time	:	1 Years
NOAEL	:	2 mg/cm ²
Result	:	negative

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

May damage the unborn child.

Components:**Petrolatum:**

Effects on fertility	:	Test Type: Reproduction/Developmental toxicity screening test
		Species: Rat
		Application Route: Ingestion
		Result: negative
		Remarks: Based on data from similar materials

Effects on fetal development	:	Test Type: Embryo-fetal development
		Species: Rat
		Application Route: Skin contact
		Result: negative
		Remarks: Based on data from similar materials

Salicylic acid:

Effects on fetal development	:	Test Type: Embryo-fetal development
		Species: Rat
		Application Route: Subcutaneous
		Developmental Toxicity: LOAEL: 380 mg/kg body weight
		Result: Maternal toxicity observed., Embryo-fetal toxicity.

SAFETY DATA SHEET



Betamethasone / Salicylic Acid Ointment Formulation

Version 3.7 Revision Date: 04/09/2021 SDS Number: 1841153-00012 Date of last issue: 10/10/2020
Date of first issue: 08/21/2017

Test Type: Embryo-fetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 80 mg/kg body weight
Result: No effects on fetal development.

Reproductive toxicity - Assessment : Suspected of damaging the unborn child.

Betamethasone:

Effects on fetal development : Species: Rabbit
Application Route: Intramuscular
Developmental Toxicity: LOAEL: 0.05 mg/kg body weight
Result: Fetotoxicity., Malformations were observed.

Species: Rat
Application Route: Subcutaneous
Developmental Toxicity: LOAEL: 0.42 mg/kg body weight
Result: Malformations were observed.

Species: Mouse
Application Route: Intramuscular
Developmental Toxicity: LOAEL: 1 mg/kg body weight
Result: Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Causes damage to organs (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) through prolonged or repeated exposure.

Components:

Betamethasone:

Target Organs : Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Petrolatum:

Species : Rat
NOAEL : 5,000 mg/kg
Application Route : Ingestion
Exposure time : 2 y

Betamethasone / Salicylic Acid Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
3.7	04/09/2021	1841153-00012	Date of first issue: 08/21/2017

Paraffin oil:

Species : Rat, female
 LOAEL : 161 mg/kg
 Application Route : Ingestion
 Exposure time : 90 Days

Salicylic acid:

Species : Rat
 NOAEL : 50 mg/kg
 Application Route : Ingestion
 Exposure time : 2 y

Species : Rat
 LOAEL : 500 mg/kg
 Application Route : Oral
 Exposure time : 3 d
 Target Organs : Liver

Betamethasone:

Species : Rabbit
 LOAEL : 0.05 %
 Application Route : Skin contact
 Exposure time : 10 - 30 d
 Target Organs : Pituitary gland, Immune system, muscle

Species : Rat
 LOAEL : 0.05 %
 Application Route : Skin contact
 Exposure time : 8 Weeks
 Target Organs : thymus gland

Species : Mouse
 LOAEL : 0.1 %
 Application Route : Skin contact
 Exposure time : 8 Weeks
 Target Organs : thymus gland

Species : Dog
 LOAEL : 0.05 mg/kg
 Application Route : Oral
 Exposure time : 28 d
 Target Organs : Blood, thymus gland, Adrenal gland

Aspiration toxicity

Not classified based on available information.

Components:**Paraffin oil:**

The substance or mixture is known to cause human aspiration toxicity hazards or has to be regarded as if it causes a human aspiration toxicity hazard.

Betamethasone / Salicylic Acid Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
3.7	04/09/2021	1841153-00012	Date of first issue: 08/21/2017

Experience with human exposure

Components:

Salicylic acid:

Skin contact	:	Symptoms: Skin irritation
Eye contact	:	Symptoms: Severe irritation
Ingestion	:	Symptoms: Gastrointestinal discomfort, hearing loss, Dizziness, electrolyte imbalance

Betamethasone:

Inhalation	:	Target Organs: Adrenal gland
Skin contact	:	Symptoms: Redness, pruritis, Irritation

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Petrolatum:

Toxicity to fish	:	LL50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 203 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 10,000 mg/l Exposure time: 48 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials
Toxicity to algae/aquatic plants	:	NOEL (Pseudokirchneriella subcapitata (green algae)): >= 100 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 10 mg/l Exposure time: 21 d Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Paraffin oil:

Toxicity to fish	:	LL50 (Scophthalmus maximus (turbot)): > 100 mg/l Exposure time: 96 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EL50 (Acartia tonsa): > 100 mg/l Exposure time: 48 h Test substance: Water Accommodated Fraction

Betamethasone / Salicylic Acid Ointment For- mulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
3.7	04/09/2021	1841153-00012	Date of first issue: 08/21/2017

Remarks: Based on data from similar materials

Toxicity to algae/aquatic plants : EL50 (Skeletonema costatum (marine diatom)): > 100 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

NOELR (Skeletonema costatum (marine diatom)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Salicylic acid:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 1,380 mg/l
Exposure time: 96 h
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 870 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (Desmodesmus subspicatus (green algae)): > 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 10 mg/l
Exposure time: 21 d

Betamethasone:

Toxicity to daphnia and other aquatic invertebrates : EC50 (Americamysis): > 50 mg/l
Exposure time: 96 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 34 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 34 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.052 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

NOEC (Oryzias latipes (Japanese medaka)): 0.07 µg/l
Exposure time: 219 d
Method: OECD Test Guideline 229

Toxicity to daphnia and other : NOEC (Daphnia magna (Water flea)): 8 mg/l

SAFETY DATA SHEET



Betamethasone / Salicylic Acid Ointment Formulation

Version 3.7 Revision Date: 04/09/2021 SDS Number: 1841153-00012 Date of last issue: 10/10/2020
Date of first issue: 08/21/2017

aquatic invertebrates (Chronic toxicity)

Exposure time: 21 d
Method: OECD Test Guideline 211

Persistence and degradability

Components:

Petrolatum:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 31 %
Exposure time: 28 d
Method: OECD Test Guideline 301F
Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

Paraffin oil:

Partition coefficient: n-octanol/water : log Pow: > 4
Remarks: Calculation

Salicylic acid:

Partition coefficient: n-octanol/water : log Pow: 2.25

Betamethasone:

Partition coefficient: n-octanol/water : log Pow: 2.11

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.

SAFETY DATA SHEET



Betamethasone / Salicylic Acid Ointment Formulation

Version 3.7 Revision Date: 04/09/2021 SDS Number: 1841153-00012 Date of last issue: 10/10/2020
Date of first issue: 08/21/2017

(betamethasone)
Class : 9
Packing group : III
Labels : 9

IATA-DGR

UN/ID No. : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.
(Betamethasone)
Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 956
Packing instruction (passenger aircraft) : 956
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Betamethasone)
Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR

UN/ID/NA number : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.
(Betamethasone)
Class : 9
Packing group : III
Labels : CLASS 9
ERG Code : 171
Marine pollutant : yes(Betamethasone)
Remarks : Above applies only to containers over 119 gallons or 450 liters., Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SAFETY DATA SHEET



Betamethasone / Salicylic Acid Ointment Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
3.7	04/09/2021	1841153-00012	Date of first issue: 08/21/2017

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Reproductive toxicity
Specific target organ toxicity (single or repeated exposure)
Serious eye damage or eye irritation

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

Petrolatum	8009-03-8
Paraffin oil	8012-95-1
Salicylic acid	69-72-7

California List of Hazardous Substances

Petrolatum	8009-03-8
Paraffin oil	8012-95-1
Salicylic acid	69-72-7

California Permissible Exposure Limits for Chemical Contaminants

Petrolatum	8009-03-8
Paraffin oil	8012-95-1

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information

SAFETY DATA SHEET



Betamethasone / Salicylic Acid Ointment Formulation




Version
3.7

Revision Date:
04/09/2021

SDS Number:
1841153-00012

Date of last issue: 10/10/2020
Date of first issue: 08/21/2017

NFPA 704:



HMIS® IV:

HEALTH	*	3
FLAMMABILITY		1
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA	:	8-hour, time-weighted average
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
NIOSH REL / ST	:	STEL - 15-minute TWA exposure that should not be exceeded at any time during a workday
OSHA Z-1 / TWA	:	8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECl - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of

SAFETY DATA SHEET



Betamethasone / Salicylic Acid Ointment Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
3.7	04/09/2021	1841153-00012	Date of first issue: 08/21/2017

Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 04/09/2021

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8